Please try another search
Cartesian Therapeutics, Inc., a clinical-stage biotechnology company, engages in the provision of mRNA cell therapies for the treatment of autoimmune diseases. It develops Descartes-08, an autologous anti-BCMA RNA-engineered chimeric antigen receptor T-cell therapy, currently under Phase 2b clinical development for generalized myasthenia gravis, as well as for patients with systemic lupus erythematosus, and myeloma autoimmune basket trials for other autoimmune diseases. The company develops Descartes-15 to treat Autoimmune diseases, myeloma; and Descartes-33 which is in preclinical development for treatment of autoimmune diseases. Cartesian Therapeutics, Inc. is headquartered in Gaithersburg, Maryland.
Name | Age | Since | Title |
---|---|---|---|
Omid C. Farokhzad | 54 | 2007 | Member of Scientific Advisory Board |
Carsten Brunn | 52 | - | President, CEO & Director |
Carrie Smith Cox | 66 | - | Chairman of the Board |
Patrick J. Zenner | 77 | 2017 | Independent Director |
Timothy C. Barabe | 71 | 2016 | Independent Director |
Murat V. Kalayoglu | 50 | 2023 | Independent Director |
Michael Scott Singer | 51 | 2023 | Independent Director |
Timothy A. Springer | 76 | 2016 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review